Osteoarthritis Claim Should Require Both Knee And Hip Data - Arthritis Cmte.
Executive Summary
FDA should require osteoarthritis compounds to be studied in both the knee and hip before granting approval for an overall osteoarthritis claim, FDA's Arthritis Advisory Committee said July 21.
You may also be interested in...
OA Structural Progression Effect Size Of 50% Is "High Hurdle," PhRMA Says
FDA's proposal that an osteoarthritis "delay in structural progression" claim be supported by a greater than 50% slowing of joint space narrowing is "too high a hurdle given the state of OA science," the Pharmaceutical Research & Manufacturers of America said in Sept. 14 comments on FDA's draft OA guidance.
OA Structural Progression Effect Size Of 50% Is "High Hurdle," PhRMA Says
FDA's proposal that an osteoarthritis "delay in structural progression" claim be supported by a greater than 50% slowing of joint space narrowing is "too high a hurdle given the state of OA science," the Pharmaceutical Research & Manufacturers of America said in Sept. 14 comments on FDA's draft OA guidance.
Osteoarthritis Structure Claim May Need Phase IV Clinical Data
Osteoarthritis agents could be eligible for a "slowing of structural deterioration" claim based on x-ray data and a commitment to do Phase IV studies measuring clinical impact on pain and function, members of FDA's Arthritis Advisory Committee agreed Feb. 20.